How much did Genovis achieve in EBIT for the current year?
In the current year, Genovis has achieved an EBIT of 31.11 M SEK.
Genovis EBIT 2024
Genovis EBIT
31.11 M SEK
Ticker
GENO.ST
ISIN
SE0002485979
WKN
A0Q4ER
In 2024, Genovis's EBIT was 31.11 M SEK, a -43.31% increase from the 54.88 M SEK EBIT recorded in the previous year.
The Genovis EBIT history
| YEAR | EBIT (undefined SEK) |
|---|---|
| 2026e | 59.67 |
| 2025e | 39.78 |
| 2024e | 31.11 |
| 2023 | 54.88 |
| 2022 | 13.82 |
| 2021 | 23.4 |
| 2020 | 5.16 |
| 2019 | 10.05 |
| 2018 | 0.97 |
| 2017 | -7.84 |
| 2016 | -15.47 |
| 2015 | -16.16 |
| 2014 | -20.94 |
| 2013 | -15.75 |
| 2012 | -16.39 |
| 2011 | -13.75 |
| 2010 | -11.23 |
| 2009 | -12.55 |
| 2008 | -25.42 |
| 2007 | -12.06 |
| 2006 | -8.83 |
| 2005 | -4.12 |
| 2004 | -2.35 |
Genovis Revenue, EBIT, Net Income SE0002485979 · A0Q4ER
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Genovis, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Genovis from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Genovis’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Genovis. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Genovis’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Genovis’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Genovis’s growth potential.
Genovis Revenue, EBIT and net profit per share
| Date | Genovis Revenue | Genovis EBIT | Genovis Net Income |
|---|---|---|---|
| 2026e | 190.74 M undefined | 59.67 M undefined | 46.74 M undefined |
| 2025e | 149.43 M undefined | 39.78 M undefined | 30.05 M undefined |
| 2024e | 131.58 M undefined | 31.11 M undefined | 26.71 M undefined |
| 2023 | 158.23 M undefined | 54.88 M undefined | 61.5 M undefined |
| 2022 | 102.39 M undefined | 13.82 M undefined | 11.19 M undefined |
| 2021 | 93.02 M undefined | 23.4 M undefined | 24.78 M undefined |
| 2020 | 61.03 M undefined | 5.16 M undefined | 6.45 M undefined |
| 2019 | 60.55 M undefined | 10.05 M undefined | 9.55 M undefined |
| 2018 | 34.57 M undefined | 970,590 undefined | -1.71 M undefined |
| 2017 | 22.87 M undefined | -7.84 M undefined | -7.95 M undefined |
| 2016 | 18.54 M undefined | -15.47 M undefined | -15.03 M undefined |
| 2015 | 13.27 M undefined | -16.16 M undefined | -19.91 M undefined |
| 2014 | 8.25 M undefined | -20.94 M undefined | -22.05 M undefined |
| 2013 | 8.91 M undefined | -15.75 M undefined | -15.85 M undefined |
| 2012 | 6.08 M undefined | -16.39 M undefined | -19.92 M undefined |
| 2011 | 2.86 M undefined | -13.75 M undefined | -13.61 M undefined |
| 2010 | 1.6 M undefined | -11.23 M undefined | -11.25 M undefined |
| 2009 | 990,000 undefined | -12.55 M undefined | -17.56 M undefined |
| 2008 | 380,000 undefined | -25.42 M undefined | -27.15 M undefined |
| 2007 | 260,000 undefined | -12.06 M undefined | -8.58 M undefined |
| 2006 | 0 undefined | -8.83 M undefined | -6.42 M undefined |
| 2005 | 0 undefined | -4.12 M undefined | -3 M undefined |
| 2004 | 0 undefined | -2.35 M undefined | -1.68 M undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2004 | 0 SEK | -2.35 M SEK | -1.68 M SEK |
| 2005 | 0 SEK | -4.12 M SEK | -3 M SEK |
| 2006 | 0 SEK | -8.83 M SEK | -6.42 M SEK |
| 2007 | 260,000 SEK | -12.06 M SEK | -8.58 M SEK |
| 2008 | 380,000 SEK | -25.42 M SEK | -27.15 M SEK |
| 2009 | 990,000 SEK | -12.55 M SEK | -17.56 M SEK |
| 2010 | 1.6 M SEK | -11.23 M SEK | -11.25 M SEK |
| 2011 | 2.86 M SEK | -13.75 M SEK | -13.61 M SEK |
| 2012 | 6.08 M SEK | -16.39 M SEK | -19.92 M SEK |
| 2013 | 8.91 M SEK | -15.75 M SEK | -15.85 M SEK |
| 2014 | 8.25 M SEK | -20.94 M SEK | -22.05 M SEK |
| 2015 | 13.27 M SEK | -16.16 M SEK | -19.91 M SEK |
| 2016 | 18.54 M SEK | -15.47 M SEK | -15.03 M SEK |
| 2017 | 22.87 M SEK | -7.84 M SEK | -7.95 M SEK |
| 2018 | 34.57 M SEK | 970,590 SEK | -1.71 M SEK |
| 2019 | 60.55 M SEK | 10.05 M SEK | 9.55 M SEK |
| 2020 | 61.03 M SEK | 5.16 M SEK | 6.45 M SEK |
| 2021 | 93.02 M SEK | 23.4 M SEK | 24.78 M SEK |
| 2022 | 102.39 M SEK | 13.82 M SEK | 11.19 M SEK |
| 2023 | 158.23 M SEK | 54.88 M SEK | 61.5 M SEK |
| 2024e | 131.58 M SEK | 31.11 M SEK | 26.71 M SEK |
| 2025e | 149.43 M SEK | 39.78 M SEK | 30.05 M SEK |
| 2026e | 190.74 M SEK | 59.67 M SEK | 46.74 M SEK |
Genovis stock margins SE0002485979 · A0Q4ER
The Genovis margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Genovis. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Genovis.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Genovis's sales revenue. A higher gross margin percentage indicates that the Genovis retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Genovis's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Genovis's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Genovis's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Genovis. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Genovis's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Genovis Margin History
| Genovis Gross margin | Genovis Profit margin | Genovis EBIT margin | Genovis Profit margin |
|---|---|---|---|
| 2026e | 72.2 % | 31.28 % | 24.51 % |
| 2025e | 72.2 % | 26.62 % | 20.11 % |
| 2024e | 72.2 % | 23.64 % | 20.3 % |
| 2023 | 72.2 % | 34.68 % | 38.87 % |
| 2022 | 58.28 % | 13.5 % | 10.93 % |
| 2021 | 63.78 % | 25.15 % | 26.64 % |
| 2020 | 63.81 % | 8.46 % | 10.56 % |
| 2019 | 64.64 % | 16.6 % | 15.77 % |
| 2018 | 58.31 % | 2.81 % | -4.95 % |
| 2017 | 31.43 % | -34.26 % | -34.76 % |
| 2016 | -45.97 % | -83.43 % | -81.07 % |
| 2015 | 81.47 % | -121.8 % | -150.02 % |
| 2014 | -94.06 % | -253.82 % | -267.27 % |
| 2013 | -50.06 % | -176.77 % | -177.89 % |
| 2012 | -94.24 % | -269.57 % | -327.63 % |
| 2011 | -164.69 % | -480.77 % | -475.87 % |
| 2010 | -324.38 % | -701.87 % | -703.13 % |
| 2009 | -502.02 % | -1,267.68 % | -1,773.74 % |
| 2008 | -2,352.63 % | -6,689.47 % | -7,144.74 % |
| 2007 | -2,150 % | -4,638.46 % | -3,300 % |
| 2006 | 72.2 % | 0 % | 0 % |
| 2005 | 72.2 % | 0 % | 0 % |
| 2004 | 72.2 % | 0 % | 0 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2004 | 72.2 % | 0 % | 0 % |
| 2005 | 72.2 % | 0 % | 0 % |
| 2006 | 72.2 % | 0 % | 0 % |
| 2007 | -2,150 % | -4,638.46 % | -3,300 % |
| 2008 | -2,352.63 % | -6,689.47 % | -7,144.74 % |
| 2009 | -502.02 % | -1,267.68 % | -1,773.74 % |
| 2010 | -324.38 % | -701.87 % | -703.13 % |
| 2011 | -164.69 % | -480.77 % | -475.87 % |
| 2012 | -94.24 % | -269.57 % | -327.63 % |
| 2013 | -50.06 % | -176.77 % | -177.89 % |
| 2014 | -94.06 % | -253.82 % | -267.27 % |
| 2015 | 81.47 % | -121.8 % | -150.02 % |
| 2016 | -45.97 % | -83.43 % | -81.07 % |
| 2017 | 31.43 % | -34.26 % | -34.76 % |
| 2018 | 58.31 % | 2.81 % | -4.95 % |
| 2019 | 64.64 % | 16.6 % | 15.77 % |
| 2020 | 63.81 % | 8.46 % | 10.56 % |
| 2021 | 63.78 % | 25.15 % | 26.64 % |
| 2022 | 58.28 % | 13.5 % | 10.93 % |
| 2023 | 72.2 % | 34.68 % | 38.87 % |
| 2024e | 72.2 % | 23.64 % | 20.3 % |
| 2025e | 72.2 % | 26.62 % | 20.11 % |
| 2026e | 72.2 % | 31.28 % | 24.51 % |
Genovis Aktienanalyse
What does Genovis do?
Genovis AB is a Swedish company that offers biotechnology solutions for drug research and diagnostic industries. The company was founded in Lund, Sweden in 1999 and currently employs over 30 employees. Genovis began with the development of enzymes for protein-based therapeutics, but over time expanded its business to include enzymes for improved analysis methods in mass spectrometry. Genovis has become a leading provider of innovative enzyme solutions and proteomics tools for biomedical research. The company's business model is based on providing specially developed enzymes and proteomics tools to companies in drug research and diagnostic industries. Genovis has two main business areas: marketing enzymes and providing peptide synthesis services. The first business area is the marketing of enzymes for the separation of glycosylated proteins in mass spectrometry. The company develops and produces these enzymes for various applications such as Alzheimer's research, cancer research, and infectious diseases. Genovis is also an important provider of enzymes for the investigation of antibody-drug conjugates used in novel therapeutic approaches. The second business area is providing peptide synthesis services. The company also has a diversified biotechnology infrastructure and offers analysis and synthesis services for peptides in various fields, such as immunotherapy and diagnostics. Genovis' product portfolio includes a variety of enzymes that have broad application in drug research and diagnostic industries. This includes enzymes for antibody proteolysis, enzymes for the synthesis of glycoconjugates, and enzymes for conjugated protein analysis. In addition, the company also offers specialized kits for protein analysis. Genovis kits always include all necessary components such as proteases, buffer systems, and instructions to conduct the offered experiments. In conclusion, Genovis is a leading company in the biotechnology industry that offers innovative enzyme solutions and proteomics tools for a variety of applications in medical research and diagnostics. With its diversified biotechnology infrastructure and dedicated employees, the company can meet the growing needs of its customers in the science and industry sectors and has become a key partner in the healthcare industry. Genovis ist eines der beliebtesten Unternehmen auf Eulerpool.com.EBIT Details
Analyzing Genovis's EBIT
Genovis's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.
Year-to-Year Comparison
A yearly comparison of Genovis's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.
Impact on Investments
Genovis's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.
Interpreting EBIT Fluctuations
Fluctuations in Genovis’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.
Frequently Asked Questions about Genovis stock
What is EBIT?
EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Genovis.
How has the EBIT of Genovis developed in recent years?
The EBIT of Genovis has increased by -43.308% decreased compared to the previous year.
What does EBIT mean for investors?
EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.
Why is EBIT an important indicator for investors?
Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.
Why do EBIT values fluctuate?
EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.
What role does tax burden play in EBIT?
Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.
How is EBIT presented in the balance sheet of the company Genovis?
The EBIT of Genovis is listed in the income statement.
Can EBIT be used as a single indicator for evaluating a company?
EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.
Why is EBIT not equal to net profit?
The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.
How much dividend does Genovis pay?
Over the past 12 months, Genovis paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Genovis is expected to pay a dividend of 0 SEK.
What is the dividend yield of Genovis?
The current dividend yield of Genovis is .
When does Genovis pay dividends?
Genovis pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Genovis?
Genovis paid dividends every year for the past 0 years.
What is the dividend of Genovis?
For the upcoming 12 months, dividends amounting to 0 SEK are expected. This corresponds to a dividend yield of 0 %.
In which sector is Genovis located?
Genovis is assigned to the 'Health' sector.
Wann musste ich die Aktien von Genovis kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Genovis from 11/1/2024 amounting to 0 SEK, you needed to have the stock in your portfolio before the ex-date on 11/1/2024.
When did Genovis pay the last dividend?
The last dividend was paid out on 11/1/2024.
What was the dividend of Genovis in the year 2023?
In the year 2023, Genovis distributed 0 SEK as dividends.
In which currency does Genovis pay out the dividend?
The dividends of Genovis are distributed in SEK.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Genovis
Our stock analysis for Genovis Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Genovis Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
